The Fort Worth Press - Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit

USD -
AED 3.6725
AFN 64.999753
ALL 81.357903
AMD 360.070206
ANG 1.789785
AOA 916.999886
ARS 1547.804802
AUD 1.431967
AWG 1.8
AZN 1.698444
BAM 1.749538
BBD 2.014491
BDT 124.528133
BGN 1.747831
BHD 0.377583
BIF 3003.578138
BMD 1
BND 1.281242
BOB 12.077109
BRL 5.495098
BSD 1.000179
BTN 94.816173
BWP 13.835763
BYN 2.972269
BYR 19600
BZD 2.011629
CAD 1.399245
CDF 2310.000029
CHF 0.820625
CLF 0.024903
CLP 980.079958
CNY 6.648298
CNH 6.66905
COP 3221.04
CRC 453.886752
CUC 1
CUP 24.004938
CVE 98.634512
CZK 21.749295
DJF 178.109947
DKK 6.678475
DOP 60.273458
DZD 136.097969
EGP 55.310203
ERN 15
ETB 164.160301
EUR 0.89361
FJD 2.24675
FKP 0.745229
GBP 0.744857
GEL 2.594977
GGP 0.745229
GHS 11.657572
GIP 0.745229
GMD 73.501199
GNF 8859.468647
GTQ 7.64648
GYD 209.660034
HKD 7.84545
HNL 26.882427
HRK 6.76901
HTG 131.102375
HUF 325.79404
IDR 18146
ILS 3.16155
IMP 0.745229
INR 94.68185
IQD 1516.318471
IRR 1879653.99949
ISK 121.68022
JEP 0.745229
JMD 158.643546
JOD 0.709044
JPY 158.455035
KES 129.960118
KGS 87.449896
KHR 4085.338581
KMF 440.000264
KPW 899.999961
KRW 1343.319953
KWD 0.31148
KYD 0.833527
KZT 452.670185
LAK 22526.165131
LBP 89568.029341
LKR 332.77574
LRD 170.033098
LSL 16.671885
LTL 2.95274
LVL 0.60489
LYD 6.418198
MAD 9.82937
MDL 18.093747
MGA 4540.656588
MKD 55.003284
MMK 2099.543828
MNT 3601.136904
MOP 8.083013
MRU 40.599338
MUR 47.297294
MVR 15.459954
MWK 1734.315528
MXN 18.67232
MYR 4.075298
MZN 63.902382
NAD 16.67181
NGN 1344.779601
NIO 36.81009
NOK 9.286015
NPR 151.705877
NZD 1.78017
OMR 0.3845
PAB 1.000358
PEN 3.4665
PGK 4.486924
PHP 63.492959
PKR 276.680651
PLN 3.94486
PYG 5974.621946
QAR 3.646073
RON 4.773984
RSD 105.071011
RUB 81.627534
RWF 1479.291529
SAR 3.764539
SBD 8.058206
SCR 13.710048
SDG 601.491994
SEK 9.801555
SGD 1.280875
SHP 0.748335
SLE 22.898941
SLL 20969.504398
SOS 571.607478
SRD 37.542025
STD 20697.981008
STN 21.916093
SVC 8.752125
SYP 13001.999685
SZL 16.65623
THB 33.756957
TJS 9.191837
TMT 3.5
TND 2.988653
TOP 2.40776
TRY 49.997797
TTD 6.780571
TWD 32.801801
TZS 2643.994985
UAH 45.664104
UGX 4225.799382
UYU 40.208782
UZS 11927.721621
VES 887.479805
VND 25766
VUV 118.901474
WST 2.774695
XAF 586.169905
XAG 0.02002
XAU 0.000254028253
XCD 2.70255
XCG 1.802576
XDR 0.707052
XOF 586.169905
XPF 106.682172
YER 236.199248
ZAR 16.58749
ZMK 9001.202813
ZMW 20.269255
ZWL 321.999592
SSP 5745.200537
MXV 2.102322
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit
Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit

Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit

LAS VEGAS, NV / ACCESS Newswire / April 16, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that following Ainnova's sponsorship and its CEO's key role at the 2025 Healthcare Innovation Summit in Mexico City, both Avant and Ainnova, through their joint venture, Ai-nova Acquisition Corp. (AAC), are building on Ainnova's strong presence in Mexico by expanding its footprint across Latin America.

Text size:

Ainnova has initiated its first commercial pilots in both Chile and the Dominican Republic to work directly with prestigious hospitals that cover the full spectrum of care - from primary to highly specialized services. These pilot programs aim to demonstrate, (i) cost reduction in preventive diagnostics; (ii) increased efficiency in medical resource allocation and patient flow; (iii) enhanced institutional reputation driven by technological innovation; and (iv) improved profitability for participating healthcare centers through optimized patient referrals.

The pilot programs leverage Ainnova's proprietary Vision AI platform to identify health risks in real time, which enable seamless referrals for specialty care or further diagnostic tests when a positive risk is detected. The broader vision for the joint venture involves deploying an automated, low-cost retinal imaging device integrated with its AI-driven platform to deliver comprehensive preventive risk screening. From just two retinal images, blood pressure and some lab test information, the system will assess risks for: cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.

Avant has partnered with Ainnova to form AAC so the two companies can advance and commercialize Ainnova's technology portfolio worldwide. AAC has the global licensing rights for the portfolio, including its Vision AI platform and its versatile retinal cameras.

Avant and Ainnova have identified Brazil and the United States as key strategic markets. Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.

At the same time, Ainnova is advancing its regulatory roadmap for the U. S. The objective is to begin clinical trials in the coming months to obtain FDA approval and commercialize its technology in the U.S. - initially targeting markets where reimbursement codes for diabetic retinopathy are already approved.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies, Inc.
[email protected]

SOURCE: Avant Technologies, Inc.



View the original press release on ACCESS Newswire

K.Ibarra--TFWP